12/12
07:36 am
zlab
Zai Lab Announces Participation in Investor Conference in January 2025 [Yahoo! Finance]
Medium
Report
Zai Lab Announces Participation in Investor Conference in January 2025 [Yahoo! Finance]
12/12
07:30 am
zlab
Zai Lab Announces Participation in Investor Conference in January 2025
Medium
Report
Zai Lab Announces Participation in Investor Conference in January 2025
12/5
04:43 am
zlab
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? [Yahoo! Finance]
Low
Report
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? [Yahoo! Finance]
12/2
01:32 pm
zlab
Novocure seeks approval after pancreatic cancer wearable scores at Phase III [Yahoo! Finance]
Low
Report
Novocure seeks approval after pancreatic cancer wearable scores at Phase III [Yahoo! Finance]
12/2
10:17 am
zlab
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients [Yahoo! Finance]
Low
Report
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients [Yahoo! Finance]
12/2
07:09 am
zlab
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer [Yahoo! Finance]
Low
Report
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer [Yahoo! Finance]
12/2
07:02 am
zlab
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
Low
Report
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
11/27
11:10 pm
zlab
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug List [Yahoo! Finance]
Low
Report
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug List [Yahoo! Finance]
11/27
11:05 pm
zlab
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
Low
Report
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
11/21
04:00 am
zlab
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
Low
Report
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
11/18
09:15 am
zlab
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
Medium
Report
Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
11/15
08:03 am
zlab
Analyst Estimates: Here's What Brokers Think Of Zai Lab Limited (NASDAQ:ZLAB) After Its Third-Quarter Report [Yahoo! Finance]
Medium
Report
Analyst Estimates: Here's What Brokers Think Of Zai Lab Limited (NASDAQ:ZLAB) After Its Third-Quarter Report [Yahoo! Finance]
11/14
07:49 pm
zlab
Zai Lab Announces Pricing of Public Offering of American Depositary Shares [Yahoo! Finance]
Low
Report
Zai Lab Announces Pricing of Public Offering of American Depositary Shares [Yahoo! Finance]
11/14
07:43 pm
zlab
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
Low
Report
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
11/14
09:08 am
zlab
Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities [Yahoo! Finance]
Medium
Report
Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities [Yahoo! Finance]
11/14
08:02 am
zlab
Zai Lab Third Quarter 2024 Earnings: EPS Beats Expectations [Yahoo! Finance]
Medium
Report
Zai Lab Third Quarter 2024 Earnings: EPS Beats Expectations [Yahoo! Finance]
11/13
04:14 pm
zlab
Zai Lab Announces Proposed Public Offering of American Depositary Shares [Yahoo! Finance]
Medium
Report
Zai Lab Announces Proposed Public Offering of American Depositary Shares [Yahoo! Finance]
11/13
04:12 pm
zlab
Zai Lab Announces Proposed Public Offering of American Depositary Shares
Medium
Report
Zai Lab Announces Proposed Public Offering of American Depositary Shares
11/13
02:14 am
zlab
Zai Lab Ltd (ZLAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Path to Profitability [Yahoo! Finance]
Low
Report
Zai Lab Ltd (ZLAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Path to Profitability [Yahoo! Finance]
11/12
02:02 pm
zlab
Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]
Low
Report
Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]
11/12
07:23 am
zlab
Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo [Yahoo! Finance]
Low
Report
Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo [Yahoo! Finance]
11/12
06:30 am
zlab
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
Medium
Report
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
11/11
07:30 am
zlab
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
Low
Report
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
10/29
07:30 am
zlab
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
Medium
Report
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
10/25
12:34 pm
zlab
Zai Lab Limited (NASDAQ: ZLAB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Zai Lab Limited (NASDAQ: ZLAB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.